Core Insights - PMV Pharmaceuticals announced the publication of Phase 1 results for rezatapopt in the New England Journal of Medicine, demonstrating its potential in treating advanced solid tumors with a TP53 Y220C mutation [1][2][4] Group 1: Study Results - The Phase 1 portion of the PYNNACLE clinical trial involved 77 heavily pretreated patients, focusing on safety, pharmacokinetics, and determining the maximum tolerated dose of rezatapopt [3][6] - Objective responses were observed across multiple tumor types, with clinical activity linked to selective binding to the Y220C pocket and restoration of wild-type p53 function [3] - The overall response rate (ORR) across all cohorts was 34% (35 out of 103 patients), with a 46% ORR (22 out of 48 patients) specifically in ovarian cancer [4] Group 2: Drug Information - Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate p53 by selectively binding to the p53 Y220C mutant protein [5] - The FDA has granted Fast Track designation to rezatapopt for treating locally advanced or metastatic solid tumors with a p53 Y220C mutation [5] Group 3: Future Plans - The company plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027 [4] - The ongoing Phase 2 portion of the PYNNACLE trial aims to evaluate the efficacy of rezatapopt in various solid tumors with TP53 Y220C and KRAS wild-type mutations [6]

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025 Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for th ...

Q4 and Full Year 2025 Results Conference call and webcast for investors and analysts FEBRUARY 26, 2026 Disclosures Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, constitute forward looking statements. Examples of such forward-looking statements include statements regarding BeOne's research, discovery, preclinical and clinical programs and plans, including proof of concept timing, ...

Indivior, Powering Recovery, Renewing Hope. Q4 and FY 2025 Financial Results February 26, 2026 IMPORTANT CAUTIONARY STATEMENT REGARDING FORWARD- LOOKING STATEMENTS Execution Against the Indivior Action Agenda Joe Ciaffoni, CEO Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking stat ...

NASDAQ: PHAT Today's Agenda Business Update FOURTH QUARTER & FULL YEAR 2025 EARNINGS CONFERENCE CALL FEBRUARY 2026 Steven Basta, President & Chief Executive Officer Financial Update Sanjeev Narula, Chief Financial and Business Officer Closing Remarks Steven Basta, President & Chief Executive Officer Question & Answer Steven Basta, President & Chief Executive Officer Sanjeev Narula, Chief Financial and Business Officer 2 Safe harbor This presentation contains forward-looking statements. All statements other ...

– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash ...

Key TakeawaysEli Lilly (LLY) reported that its oral GLP-1, orforglipron, achieved a 9.2% weight loss in Phase 3 trials, significantly outperforming Novo Nordisk's oral semaglutide.Toronto-Dominion Bank (TD) beat Q1 earnings estimates with an adjusted EPS of CAD 2.44, supported by adjusted revenue of CAD 16.63 billion.Danish Prime Minister Mette Frederiksen officially called for a parliamentary election on March 24, citing ongoing conflicts regarding Greenland and new wealth tax proposals.Stellantis (STLA) i ...

Indivior, Powering Recovery, Renewing Hope. Investor Presentation February 26, 2026 IMPORTANT CAUTIONARY STATEMENT REGARDING FORWARD- LOOKING STATEMENTS This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Company's financial guidance for 2026, including total net revenue, SUBLOCADE® net revenue, non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, and cash flow from opera ...

Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Fina ...

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme.The clinical administration follows the Company's ...